Key result
Obesity in women with polycystic ovary syndrome was associated with significantly higher frequencies of abnormal fasting plasma glucose (57.3% vs 17.1%) and dyslipidemia compared to normal-weight patients.
Why the study?
BMI status is theorized to impact plasma glucose and lipid parameters in women with polycystic ovary syndrome, but this needed investigation among women in Port Harcourt, Nigeria.
Does BMI impact plasma glucose and lipid parameters in women with polycystic ovary syndrome?
Cross-Sectional (n=231)
No
Does BMI impact plasma glucose and lipid parameters in women with polycystic ovary syndrome?
Absolute Event Rate: 57.3% vs 17.1%
p-value: p=0.001
Increasing BMI in women with PCOS is strongly associated with worsening fasting plasma glucose and lipid profiles, highlighting the need for weight reduction as a therapeutic target.
Background: BMI status is theorized to impact on the plasma glucose and lipid parameters of women with polycystic ovary syndrome. Hence, this study was instituted to investigate this theory among women with polycystic ovary syndrome in Port Harcourt, Nigeria.Methods: Medical records of 231 women with PCOS visiting a tertiary health center over a consecutive 10-year period were retrospectively acquired and analyzed. The obtained records were age, weight, height, calculated BMI, fasting plasma glucose and lipid profile (total cholesterol, triglycerides, high-density lipoprotein and low-density lipoprotein). The records were analyzed using Shapiro-Wilk, descriptive, chi-square, two-way analysis of variance, and Pearson’s tests. A two-tailed p-value of <0.05 was considered significant.Results: Overweight and obesity was recorded among 33.3% and 45.5% of the study cohorts respectively. The obese cohorts had higher plasma levels and abnormal frequency of fasting glucose (<0.001), total cholesterol (<0.001), triglycerides (<0.001), high-density lipoprotein (<0.001) and low-density lipoprotein (<0.001) status than the normal weight and overweight cohorts. BMI correlated weakly with glucose (r=0.259; p = 0.003), inversely but weakly with high-density lipoprotein (r: -0.373 p<0.001) and weakly with triglycerides (r=0.316; p<0.001) among overweight cohorts. BMI correlated strongly with fasting glucose (r=0.578; p< 0.001), strongly with total cholesterol (r=0.840; p<0.001), moderately but inversely with high-density (r=-0.490; p=0.004), strongly with triglycerides (r=0.753; p<0.001) and strongly with low-density lipoprotein (r=0.759; p<0.001) among the obese cohorts.Conclusions: Abnormal plasma glucose and lipid parameters seem to be prevalent among obese PCOS patients. Therefore, weight reduction should be a therapeutic target during their treatment.
No takes yet. Share an insight, caveat, or question.
Green et al. (2018) conducted a cross-sectional in Polycystic ovary syndrome (PCOS) (n=231). Obesity (BMI >30 kg/m2) vs. Normal weight (BMI 18.5-24.9 kg/m2) was evaluated on Abnormal fasting plasma glucose (>5.6 mmol/l) (p=0.001). Obesity in women with polycystic ovary syndrome was associated with significantly higher frequencies of abnormal fasting plasma glucose (57.3% vs 17.1%) and dyslipidemia compared to normal-weight patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: